Multiple sclerosis prevalence in the United States commercially insured population

Neurology

Volumn 86, Issue 11, 2016, Pages 1014-1021

  Dilokthornsakul, Piyameth ^a,b   Valuck, Robert J ^a   Nair, Kavita V ^a   Corboy, John R ^c   Allen, Richard R ^d   Campbell, Jonathan D ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b NARESUAN UNIVERSITY   (Thailand)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d Peak Statistical Services   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ALGORITHM; ARTICLE; CHILD; DATA BASE; FEMALE; HEALTH INSURANCE; HUMAN; ICD-9; INSURANCE; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; OUTPATIENT; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UNITED STATES; VERY ELDERLY; YOUNG ADULT; ADOLESCENT; FACTUAL DATABASE; HEALTH SURVEY; PRESCHOOL CHILD; PROCEDURES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; DATABASES, FACTUAL; FEMALE; HUMANS; INSURANCE, HEALTH; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; POPULATION SURVEILLANCE; PREVALENCE; RETROSPECTIVE STUDIES; UNITED STATES; YOUNG ADULT;

EID: 84961266491     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000002469     Document Type: Article

References (24)

1. Zwibel HL, Smrtka J. Improving quality of life in multiple sclerosis: an unmet need. Am J Manag Care 2011;17 (suppl 5):S139-S145
2. Phillips CJ. The cost of multiple sclerosis and the cost effectiveness of disease-modifying agents in its treatment. CNS Drugs 2004;18:561-574
3. Nortvedt MW, Riise T, Myhr KM, Nyland HI. Quality of life in multiple sclerosis: measuring the disease effects more broadly. Neurology 1999;53:1098-1103
4. Rao SM, Leo GJ, Ellington L, Nauertz T, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis: II: impact on employment and social functioning. Neurology 1991;41:692-696
5. Adelman G, Rane SG, Villa KF. The cost burDen of multiple sclerosis in the United States: a systematic review of the literature. J Med Econ 2013;16:639-647
6. Anderson DW, Ellenberg JH, Leventhal CM, Reingold SC, Rodriguez M, Silberberg DH. Revised estimate of the prevalence of multiple sclerosis in the United States. Ann Neurol 1992;31:333-336
7. Baum HM, Rothschild BB. The incidence and prevalence of reported multiple sclerosis. Ann Neurol 1981;10: 420-428
8. Campbell JD, Ghushchyan V, McQueen RB, et al. BurDen of multiple sclerosis on direct, indirect costs and quality of life: national US estimates. Mult Scler Relat Disord 2014;3:227-236
9. Noonan CW, Kathman SJ, White MC. Prevalence estimates for MS in the United States and evidence of an increasing trend for women. Neurology 2002;58: 136-138
10. Mayr WT, Pittock SJ, McClelland RL, Jorgensen NW, Noseworthy JH, Rodriguez M. Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985-2000. Neurology 2003;61:1373-1377
11. Noonan CW, Williamson DM, Henry JP, et al. The prevalence of multiple sclerosis in 3 US communities. Prev Chronic Dis 2010;7:A12
12. National Multiple Sclerosis Society. Who Gets MS?. [online]. Available at: http://www.nationalmssociety.org/What-is-MS/Who-Gets-MS. Accessed March 3, 2015
13. United States Census Bureau. The 2012 Statistical Abstract [online]. Available at: http://www.census.gov/en.html. Accessed October 15, 2015
14. Delaye D. Map of the United States [Online]. Available at: https://drive.google.com/templates?. q5delaye&sort5hottest&view5public&ddrp51#. Accessed April 2, 2015
15. Trisolini M, Honeycutt A, Wiener J, Lesesne S. Global Economic Impact of Multiple Sclerosis. Research Triangle Park, NC RTI International; 2010
16. Asche CV, Singer ME, Jhaveri M, Chung H, Miller A. All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States. J Manag Care Pharm 2010;16:703-712
17. Goldberg LD, Edwards NC, Fincher C, Doan QV, Al-Sabbagh A, Meletiche DM. Comparing the costeffectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis. J Manag Care Pharm 2009;15:543-555
18. Loma I, Heyman R. Multiple sclerosis: pathogenesis and treatment. Curr Neuropharmacol 2011;9:409-416
19. Arias M, Dapena D, Arias-Rivas S, et al. Late onset multiple sclerosis. Neurologia 2011;26:291-296
20. Martinelli V, Rodegher M, Moiola L, Comi G. Late onset multiple sclerosis: clinical characteristics, prognostic factors and differential diagnosis. Neurol Sci 2004;25(suppl 4):S350-S355
21. Polliack ML, Barak Y, Achiron A. Late-onset multiple sclerosis. J Am Geriatr Soc 2001;49:168-171
22. Marrie RA, Yu N, Blanchard J, Leung S, Elliott L. The rising prevalence and changing age distribution of multiple sclerosis in Manitoba. Neurology 2010;74:465-471
23. Mackenzie IS, Morant SV, Bloomfield GA, MacDonald TM, O'Riordan J. Incidence and prevalence of multiple sclerosis in the UK 1990-2010: a descriptive study in the General Practice Research Database. J Neurol Neurosurg Psychiatry 2014; 85:76-84
24. Kurtzke JF, Beebe GW, Norman JE Jr. Epidemiology of multiple sclerosis in U.S. veterans: 1: race, sex, and geographic distribution. Neurology 1979;29:1228-1235